

Equities

9 February 2012 | 15 pages

Bharti Airtel (BRTI.BO)


3Q Below - Tariffs or Mins? Time to Find the Right Balance

- Weak overall though includes one-offs 3Q EBITDA at Rs59.6bn (+2.5%qoq) came in 5% below hit by weak mobile, Telemedia and Enterprise though some of it was due to one-off 1) Wireless product provisioning in Bangladesh, 2) Telemedia adverse regulation related to telemarketing and 3) a lumpy market spend. Meanwhile PAT at Rs10.1bn was further hit by high capitalization charge and tax. We cut FY12-14E EBITDA by 5%. Hit on EPS (FY13-14E) is higher given small base though comes almost entirely from EBITDA cut. TP as a result declines to Rs425.
- Middle approach on tariffs likely now The industry clearly has not matured and there continues to remain price arbitrage. Bharti's strategy of keeping tariffs high has not worked reflected in slow mins growth and falling rev market shr. While rev/min improved 4% in last 2 quarters, overall traffic fell 0.5%. We believe the company will have to re-think the strategy the approach is likely to be nuanced with selective cuts to regain lost market share. This approach, while going against its strategy of keeping tariffs firm, may be necessitated by market dynamics. As a result we moderate rev/min assumptions though with an uptick in traffic growth.
- Africa Near-term disruption but we remain confident on value accretion Topline (LC) grew 5%qoq though mins growth was only 3%qoq (~9-10% in previous 2). Mgmt attributed this to disruption in Nigeria and elections in DRC. Mins growth is likely to remain muted in 4Q too given disruption in Nigeria in early Jan. Encouragingly, peak capex is behind (some concern had been raised given MTN's high capex guidance early in the year).
- Still Top Pick; Street may wait for improvement Continue to prefer Bharti over Idea. While upside in Bharti may be modest, it offers downside protection insulated from SC ruling and strong FCF cushions impact from large regulatory outgo while other operators face business disruption (varying degrees) due to cancellations. Near term however, the Street may want to see evidence of reversal in market share loss (should be reflected in 4Q) before it gets reflected in stock price.

- Company Update
- Target Price Change
- Estimate Change

1
Rs354.00
Rs425.00
20.1%
0.6%
20.6%
Rs1,344,326M
US\$27,365M

Price Performance (RIC: BRTI.BO, BB: BHARTI IN)



Statistical Abstract

Source: Powered by dataCentral

Year to	Net Profit	Diluted EPS	EPS growth	P/E	P/B	ROE	Yield
31 Mar	(RsM)	(Rs)	(%)	(x)	(x)	(%)	(%)
2010A	91,025	23.97	7.4	14.8	3.2	25.4	0.3
2011A	70,198	18.48	-22.9	19.2	2.8	15.6	0.3
2012E	48,056	12.65	-31.5	28.0	2.6	9.5	0.6
2013E	88,854	23.40	84.9	15.1	2.2	15.8	1.1
2014E	109,957	28.95	23.7	12.2	2.0	17.3	2.3

Gaurav Malhotra, CFA

+91-22-6631-9885 gaurav.a.malhotra@citi.com

Ravi Sarathy

+852-2501-2773 ravi.sarathy@citi.com

Jitender Tokas jitender.tokas@citi.com

See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures.

Citi Investment Research & Analysis is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

BRTI.BO: Fiscal year end 3 Profit & Loss (Rsm)	1-Mar 2010	2011	2012E	2013E	2014F	Price: Rs354.00; T Valuation ratios	P: Rs425.00; M 2010	larket Cap: 2011	Rs1,344,32 2012E	26m; Reco 2013E	mm: Buy 2014E
Sales revenue	396,150	594,672	714,668	791,248	843,377		14.8	19.2	28.0	15.1	12.2
Cost of sales	-54,600	-356,547	-395,336	-413,412	-429,455		3.2	2.8	2.6	2.2	2.0
Gross profit	341,550	238,125	319,332	377,836		EV/EBITDA (x)	8.9	8.2	8.1	6.8	5.8
Gross Margin (%)	86.2	40.0	44.7	47.8		FCF yield (%)	2.2	-6.6	2.4	8.2	10.
EBITDA	156,531	199,664	237,220	280,496		Dividend yield (%)	0.3	0.3	0.6	1.1	2.3
EBITDA Margin (%)	39.5	33.6	33.2	35.4		Payout ratio (%)	4	5	16	17	28
Depreciation (75)	-53,885	-86,980	-101,238	-113,013		ROE (%)	25.4	15.6	9.5	15.8	17.3
Amortisation	-2,836	-15,086	-29.663	-17,593		Cashflow (Rsm)	2010	2011	2012E	2013E	2014E
EBIT	99,810	97,598	106,319	149,891		EBITDA	156,531	199,664	237,220	280,496	316,567
EBIT Margin (%)	25.2	16.4	14.9	18.9		Working capital	-10,706	9,577	-30,757	-34,633	-22,799
Net interest	5,782	-21,813	-36,632	-28,750	-25,584	- ·	-13,677	-20,728	-34,525	-28,795	-35,799
Associates	292	0	00,002	20,700		Operating cashflow	132,149	188,513	171,938	217,068	257,970
Non-op/Except	1,093	0	0	0		Capex	-102,296	-277,877	-139,916	-106,978	-116,856
						•	413				
Pre-tax profit	106,978	75,785	69,686	121,141	•	Net acq/disposals		47,373	0	0	202
Tax	-13,959	-17,790	-21,496	-28,795	-35,799		-165	-373,991	440	271	303
Extraord./Min.Int./Pref.div.	-1,994	12,203	-135	-3,492		Investing cashflow	-102,048	-604,495	-139,475	-106,707	-116,554
Reported net profit	91,025	70,198	48,056	88,854	,	Dividends paid	-4,442	-4,428	-8,545	-17,089	-34,178
Net Margin (%)	23.0	11.8	6.7	11.2		Financing cashflow	-27,344	397,153	-38,671	-113,899	-136,059
Core NPAT	91,025	70,198	48,056	88,854	109,957	Net change in cash	2,757	-18,953	-6,209	-3,538	5,357
Per share data	2010	2011	2012E	2013E		Free cashflow to s/holde	rs 29,853	-89,364	32,023	110,090	141,113
Reported EPS (Rs)	23.97	18.48	12.65	23.40	28.95						
Core EPS (Rs)	23.97	18.48	12.65	23.40	28.95						
DPS (Rs)	1.00	1.00	2.00	4.00	8.00						
CFPS (Rs)	34.80	49.64	45.28	57.16	67.93						
FCFPS (Rs)	7.86	-23.53	8.43	28.99	37.16						
BVPS (Rs)	108.94	128.41	138.82	157.72	177.67						
Wtd avg ord shares (m)	3,798	3,798	3,798	3,798	3,798						
Wtd avg diluted shares (m)	3,798	3,798	3,798	3,798	3,798						
Growth rates	2010	2011	2012E	2013E	2014E						
Sales revenue (%)	7.2	50.1	20.2	10.7	6.6						
EBIT (%)	-4.1	-2.2	8.9	41.0	17.6						
Core NPAT (%)	7.5	-22.9	-31.5	84.9	23.7						
Core EPS (%)	7.4	-22.9	-31.5	84.9	23.7						
Balance Sheet (Rsm)	2010	2011	2012E	2013E	2014E						
Cash & cash equiv.	77,034	15,799	9,590	6,052	11,409						
Accounts receivables	24,335	54,929	66,013	73,086	77,901						
Inventory	484	2,139	2,443	2,630	2,777						
Net fixed & other tangibles	506,890	1,307,926	1,323,420	1,300,284	1,277,379						
Goodwill & intangibles	0	0	0	0	0						
Financial & other assets	37,666	84,271	85,251	86,256	87,286						
Total assets	646,409	1,465,064	1,486,717	1,468,309	1,456,753						
Accounts payable	0	0	0	0	0						
Short-term debt	0	0	0	0	0						
Long-term debt	64,619	616,708	616,625	548,836	472,841						
Provisions & other liab	139,601	324,860	306,950	281,074	272,036						
Total liabilities	204,220	941,568	923,575	829,910	744,877						
Shareholders' equity	413,700	487,668	527,179	598,944	674,722						
Minority interests	28,489	28,563	28,698	32,190	37,153						
Total equity	442,189	516,231	555,877	631,134	711,875						
• •	•										
Net debt	-12,415	600,909	607,034	542,784	461,432						

For further data queries on Citi's full coverage universe please contact CIRA Data Services Asia Pacific at CIRADataServicesAsiaPacific@citi.com or +852-2501-2791



Bharti – Shaken and should now get stirred

Bharti's topline growth from 2QFY09 to 2QFY12 has been slower compared to GSM incumbents (Vodafone/Idea) in the last past few quarters. Idea's CQGR since 2QFY09 has been 4.9% while it is 3.6% for Vodafone and Bharti's has only been 1.9%. In addition, it has also lost 310bps revenue market share (pan-India) since 2QFY09 vs. gains of 330/250bps by Idea/Vodafone respectively. The slower topline growth has generally been attributed to its larger scale while the consolidated revenue share gains for Vodafone/Idea have been linked to their new circle launches.

We analyse TRAI data (from 2QFY09 to 2QFY12) which provides excellent granularity of circle-wise operator revenues. We drill deeper to the circle level to analyze how much to attribute the growth/rev share movement to these arguments. In order to normalize for scale distortions, we have taken the top 5 circles, which together account for 45-55% of each operator's revenues. These circles include

- 1. Bharti Karnataka, Delhi, AP, TN, Bihar
- 2. **Vodafone** Delhi, Gujarat, Mumbai, TN, UP(E)
- 3. Idea Maharashtra, AP, Kerala, MP, UP(W)

Bharti lost rev market share in 4/5 top circles

Bharti has lost 90-600bps revenue share in 4 of the top 5 circles. The largest revenue contributor (Karnataka; 11% of revenues) has witnessed a 480bps loss. The only circle which saw some improvement has been Andhra Pradesh (170bps). Vodafone on the other hand has witnessed revenue share loss (70-140bps) in only 2 of its 5 circles – Mumbai and UP (E). Idea meanwhile has not seen any revenue share loss in its top 5 circles, instead gaining 50-810bps revenue market share

Expanding this beyond the top 5 circles, Bharti has lost revenue share in 16/22 circles; Vodafone on the other hand has lost in 5/22 circles while Idea has managed to improve market share across all of its circles.

Figure 1. Revenue market share and trends from 2QFY09 to 2QFY12 (last 12 quarters)

	BS	SNL	Id	ea	Voda	afone	Bh	arti	Aiı	rcel	Tata	Tele	RC	ЮМ	Un	inor
	Mkt share	Trend	Mkt share	Trend	Mkt share	Trend	Mkt share	Trend	Mkt share	Trend	Mkt share	Trend	Mkt share	Trend	Mkt share	Trend
AP	9.4%	1.1%	17.3%	0.5%	10.8%	-2.6%	39.5%	1.7%	1.6%	1.6%	11.2%	0.0%	7.3%	-5.4%	2.3%	2.3%
Assam	10.8%	-13.7%	1.9%	1.9%	13.1%	12.5%	31.0%	0.2%	23.7%	0.4%	2.5%	2.5%	16.7%	-4.0%	0.0%	0.0%
Bihar	6.2%	-5.9%	8.9%	8.9%	11.4%	11.4%	43.3%	-6.1%	4.3%	1.2%	7.6%	-0.9%	12.1%	-14.8%	3.5%	3.5%
Kolkata	4.7%	-2.5%	3.3%	3.3%	31.0%	0.9%	26.7%	-3.7%	4.1%	3.4%	11.5%	1.0%	12.5%	-8.5%	3.6%	3.6%
Gujarat	5.4%	-1.9%	17.6%	1.4%	39.1%	1.3%	17.4%	-2.4%	NA	NA	7.8%	1.5%	7.6%	-5.0%	3.4%	3.4%
Haryana	10.2%	-6.5%	21.8%	3.3%	27.9%	5.2%	17.7%	-2.9%	1.0%	1.0%	13.2%	2.2%	6.1%	-4.4%	0.0%	0.0%
HP	15.4%	-2.5%	7.6%	2.7%	8.2%	8.2%	40.4%	-7.5%	6.7%	5.5%	4.2%	-0.9%	14.4%	-8.7%	0.0%	0.0%
J&K	15.6%	-6.0%	2.2%	2.2%	8.5%	8.5%	38.5%	-29.3%	27.0%	16.5%	3.1%	3.1%	5.1%	5.0%	0.0%	0.0%
Karnataka	a 5.9%	-3.1%	8.6%	2.3%	14.5%	-1.5%	45.8%	-4.8%	1.5%	1.5%	12.0%	4.6%	7.8%	-2.8%	1.3%	1.3%
Kerala	14.7%	-1.2%	32.0%	8.1%	22.5%	5.0%	16.5%	-3.5%	2.1%	2.1%	6.0%	-0.7%	4.4%	-11.7%	0.6%	0.6%
MP	8.2%	-3.4%	30.9%	2.4%	6.1%	6.1%	25.9%	-7.3%	0.8%	0.8%	8.9%	4.4%	18.1%	-4.0%	0.0%	0.0%
Mah	6.6%	-4.0%	28.1%	2.0%	23.3%	6.4%	19.8%	-4.0%	0.9%	0.9%	10.4%	-0.9%	7.4%	-4.0%	3.0%	3.0%
NE	13.7%	-12.4%	2.5%	2.5%	11.5%	10.9%	36.6%	1.0%	25.5%	1.1%	3.0%	3.0%	7.0%	-6.4%	0.0%	0.0%
Orissa	16.0%	-6.3%	3.2%	3.2%	12.2%	11.8%	36.0%	-7.3%	7.4%	2.9%	8.6%	1.3%	12.7%	-9.5%	2.5%	2.5%
Punjab	7.6%	-6.3%	19.6%	2.0%	17.8%	3.5%	36.3%	0.3%	1.6%	1.6%	8.4%	1.8%	5.2%	-2.1%	0.0%	0.0%
Rajasthan	า 7.5%	-8.9%	10.3%	5.0%	22.4%	1.8%	42.4%	2.9%	2.2%	2.2%	6.3%	-0.6%	5.6%	-3.6%	0.0%	0.0%
TN	7.8%	-3.5%	2.2%	2.2%	23.0%	4.3%	31.2%	-0.9%	21.1%	-1.3%	5.4%	0.6%	6.2%	-4.4%	1.0%	1.0%
UP (E)	11.0%	-7.3%	11.8%	5.1%	28.6%	-0.7%	27.8%	0.7%	2.0%	2.0%	4.8%	0.6%	8.2%	-6.1%	5.4%	5.4%
UP (W)	7.7%	-5.4%	28.1%	3.6%	22.7%	-0.7%	16.9%	-0.2%	2.5%	2.5%	8.1%	0.3%	8.4%	-5.6%	5.1%	5.1%
WB	6.7%	-6.5%	3.3%	3.3%	35.8%	0.4%	25.7%	-1.7%	4.1%	1.3%	5.1%	-0.3%	10.9%	-4.9%	4.7%	4.7%
Delhi	4.9%	1.0%	10.3%	0.5%	27.1%	5.0%	35.2%	-4.0%	2.4%	2.4%	7.7%	-4.6%	11.2%	-1.4%	0.0%	0.0%
Mumbai	2.7%	-3.4%	7.2%	6.9%	31.1%	-1.4%	18.7%	-2.4%	1.9%	1.9%	13.6%	-0.7%	12.9%	-4.2%	1.8%	1.8%

Source: Citi Investment Research and Analysis

Meanwhile the industry has clearly not matured with continued price arbitrage. Bharti's strategy of keeping tariffs low clearly has not worked, reflected in a lackluster mins growth; a trend divergent when compared to its peers when seen in context to the rev/min trend witnessed since the tariff hikes (July -11).

Figure 2. T	raffic grow	th					Figure 3. F	Rev/min tre	nd (Rs)		
-	Sep-10	Dec-10	Mar-11	Jun-11	Sep-11	Dec-11		Sep-10	Dec-10	Mar-11	Jun-11
Bharti	0.2%	4.4%	6.4%	7.8%	-1.6%	1.1%	Bharti	0.44	0.44	0.43	0.43
Idea	14.3%	10.2%	9.0%	6.5%	-2.2%	7.3%	Idea	0.42	0.42	0.41	0.41
Vodafone	1.6%	5.5%	7.8%	7.0%	0.1%	NA	Vodafone	0.57	0.57	0.56	0.55

21.4%

25.4%

Source: Citi Investment Research and Analysis

69.7%

79.3%

31.3%

137.7%

Source: Citi Investment Research and Analysis, For Vodafone see trend and not absolute number since it doesn't double count on-net mins

0.40

0.32

0.31

Given the continued market share losses and muted mins growth, we believe the company will have to re-think its strategy of focusing on rev/min though we don't expect an across the board cut. The company is likely to fine tune its strategy on tariffs selectively to counter the falling revenue market share.

0.36

As a result, we tweak our wireless assumptions – moderating the rev/min increase though with higher traffic growth. Wireless margins too come down by 70-90bps as a result.

Dec-11

0.45

0.43

NA

0.28

Sep-11

0.43

0.43

0.57

0.30

Figure 4. Wireless revisions

		FY12E			FY13E		FY14E			
	Previous	New	Change	Previous	New	Change	Previous	New	Change	
Rev/min (Rs)	0.44	0.44	0.7%	0.45	0.45	-1.7%	0.46	0.45	-3.2%	
ARPU (Rs)	194	192	-1.0%	196	191	-2.5%	199	195	-2.2%	
MoU (mins)	439	431	-1.7%	433	430	-0.8%	432	437	1.1%	
Traffic Growth (%)	14.0%	12.5%	-1.6%	7.0%	7.9%	0.9%	5.9%	6.8%	0.9%	
Wireless rev (Rs m)	410,131	407,453	-0.7%	450,643	440,275	-2.3%	485,284	471,086	-2.9%	
EBITDA/min (Rs)	0.15	0.15	-0.6%	0.16	0.16	-0.6%	0.17	0.16	-5.5%	
Wireless Margins (%)	34.6%	34.2%	-0.4%	36.4%	35.6%	-0.7%	37.8%	36.9%	-0.9%	

Source: Citi Investment Research and Analysis estimates

Figure 5. EBITDA down by 5%; impact on EPS higher due to low base and comes almost entirely from EBITDA cut

Total

		FY12E			FY13E			FY14E	
	Previous	New	Change	Previous	New	Change	Previous	New	Change
EBITDA (Rs m)	249,982	237,220	-5%	295,071	280,496	-5%	334,408	316,567	-5%
EPS (Rs)	17.6	12.7	-28%	27.0	23.4	-13%	33.8	29.0	-14%

Source: Citi Investment Research and Analysis estimates

Figure 6. TP breakdown (Rs	s/share)	
	New	Old
Core business	320	344
Towerco	90	93
Zain	39	39
Regulatory outgo	-24	-24

425

Source: Citi Investment Research and Analysis

452

Quarterly Summary

Figure 7. Quarterly Financials

Rs m	3QFY12	2QFY12	3QFY11	Y/Y (%)	Q/Q (%)
Income from Services	184,767	172,698	157,560	17.3%	7.0%
Access Charges	26,309	24,000	20,327	29.4%	9.6%
Network Op. Costs	40,815	38,220	32,899	24.1%	6.8%
Staff + SGA	43,357	39,058	40,452	7.2%	11.0%
License Fee	15,435	14,510	13,502	14.3%	6.4%
EBITDA	59,585	58,151	49,816	19.6%	2.5%
PBT	15,806	15,126	15,495	2.0%	4.5%
PAT	10,113	10,270	13,033	-22.4%	-1.5%

Source: Company, Citi Investment Research and Analysis

Wireless – Muted mins growth; company likely to start taking selective cuts

Figure 8. Wireless Business Parameters

Rs m	3Q11	4Q11	1Q12	2Q12	3Q12	Remarks
Revenue	91,459	94,948	98,404	97,827	101,764	
qoq growth (%)	3.9%	3.8%	3.6%	-0.6%	4.0%	Comes primarily from rev/min increase
EBITDA	31,954	31,620	33,614	32,926	34,431	
EBITDA margin (%)	34.6	33.3	34.2	33.7	33.8	Hit by product provisioning in Bangladesh
ARPU	198	194	190	183	187	
MoU	449	449	445	423	419	
Prepaid as % of net adds	0	0	0	0	0	
Data as % of revenues	13.8	15.0	14.6	14.5	14.3	Data uptake continues, VAS impacted from adverse regulation
Number of cell sites	113,587	116,261	117,144	118,011	119,044	Steady increase
QoQ increase	3,549	2,674	883	867	1,033	•
Census towns	5,104	5,113	5,114	5,115	5,116	
Non-census towns/villages	450,293	452,215	452,719	453,148	453,294	
Population coverage	85.8%	86.1%	86.2%	86.3%	86.4%	Sustained improvement in coverage
Minutes (mn)	205,018	218,190	228,331	224,734	227,115	
qoq growth (%)	7.5%	6.4%	4.6%	-1.6%	1.1%	Primarily due to focus on rev/min
Revenue per minute (Rs)	0.44	0.43	0.43	0.43	0.45	•
Revenue per minute (paisa)	44.20	43.10	42.80	43.20	44.56	
EBITDA per minute (Rs)	0.16	0.145	0.147	0.147	0.152	Benefitted from rev/min increase
Capex per minute (Rs)	0.31	1.96	2.45	1.43	NM	

Source: Company, Citi Investment Research and Analysis

Towerco - Healthy growth in tenancy

Figure 9. Bharti Infratel/Indus Summary

Rs m	3Q11	4Q11	4Q11	4Q11	4Q11	Remarks
Revenue	21,972	22,010	22,767	23,766	24,393	Includes 42% stake of Indus
EBITDA	8,486	8,153	8,585	8,902	9,110	Healthy growth from both increase in tower count and tenancy
EBITDA margin (%)	39%	37%	38%	37%	37%	
Number of towers	32,424	32,792	32,942	33,056	33,203	Continues to grow
Tenancy	1.68	1.73	1.77	1.79	1.81	Sustained rise in tenancy
Rental/tower/month	37,859	36,599	36,203	37,117	37,623	Doesn't include pass through costs
Gross Rentals (incl. passthrus)	53,602	51,679	52,136	53,818	54,557	
Indus						
Total towers	107,789	108,586	108,992	108,998	109,101	
Tenancy	1.80	1.83	1.87	1.89	1.91	Steady improvement
Infratel consolidated						
Towers	77,695	78,398	78,689	78,835	79,025	
Tenancies	1.75	1.79	1.83	1.85	1.87	

Source: Company, Citi Investment Research and Analysis

Enterprise – Benefitted from favorable fx movement

Figure 10. Enterprise Summary

Rs m	3Q11	4Q11	1Q12	2Q12	3Q12	Remarks
Revenue	9,068	9,178	9,457	9,528	9,128	Hit from adverse regulation which impacted telemarketing
EBITDA	4,045	4,147	4,304	4,213	3,542	
EBITDA margin (%)	44.6	45.2	45.5	44.2	38.8	Should bounce back to longer-term trend of ~44%
ARPU	934	934	952	955	916	•
Coverage of towns	87	87	87	87	87	
Number of DSL subs	3,257,000	3,296,000	3,322,000	3,328,000	3,317,0	00 Decline primarily from telemarketing

Source: Company, Citi Investment Research and Analysis

Fixed line - Hit by adverse regulations

Figure 11. Fixed line and Broadband Summary parameters

Rs m	3Q11	4Q11	1Q12	2Q12	3Q12	Remarks
Revenue	10,503	10,179	10,410	11,042	11,881	Benefits from currency
EBITDA	2,260	2,619	2,303	2,371	2,008	·
EBITDA margins (%)	21.5%	25.7%	22.1%	21.5%	16.9%	Should bounce back
NLD Minutes	18,063	19,542	19,878	20,305	20,551	Sustained growth
ILD Minutes	3,192	3,047	3,119	3,519	3,529	· ·

Source: Company, Citi Investment Research and Analysis

DTH - EBITDA margins should start moving up

Figure 12. DTH Summary

Rs m	3Q11	4Q11	1Q12	2Q12	3Q12	Remarks
Revenue	2,133	2,555	2,934	3,135	3,327	
EBITDA	(150)	158	50	116	90	
EBITDA margins (%)	-7.0%	6.2%	1.7%	3.7%	2.7%	Should start accelerating
Digital TV Customers	4,932,000		6,262,000	6,614,000	7,069,000	Half of DishTV; market share of ~12-13%
ARPU (Rs)	161		163	161	160	
Monthly Churn (%)	1.2		0.7	1.2	1.2	
# Districts covered	505		550	582	587	

Source: Company, Citi Investment Research and Analysis

Africa - Hit by one-offs but longer term we remain positive

Figure 13. Africa business parameters

Rs m	3Q11	4Q11	1Q12	2Q12	3Q12	Remarks
Revenues	40,530	41,805	43,784	47,032	53,589	
% growth	4.2%	3.1%	4.7%	7.4%	13.9%	LC growth at 5%
EBITDA	7,724	10,176	11,002	12,329	14,299	
EBITDA margins	19.1%	24.3%	25.1%	26.2%	26.7%	Steady improvement
Total customer base ('000)	42,124	44,206	46,306	48,437	50,949	• •
Net additions	2042	2082	2100	2131	2512	Steady increase
Pre-paid as % of total subs	99.3%	99.3%	99.3%	99.3%	99.3%	In-line with the Indian trend
Mins (mn)	14,904	14,915	16,337	17,950	18,496	Muted growth hit by business disruption in Nigeria and elections in DRC
ARPU	7.3	7.2	7.3	7.3	7.3	
Rev/min (US\$ cents)	6.1	6.2	6.0	5.7	5.7	
MoU	120	115	121	128	125	
Churn	5.9%	6.2%	6.3%	6.1%	5.4%	Lower than India
Non-voice as % of mobile revenues	7.9%	7.8%	8.4%	8.5%	8.0%	
Traffic details						
Wireless mins	14,904	14,915	16,337	17,950	18,496	Healthy growth in the last 2 quarters
Growth	16.6%	0.1%	9.5%	9.9%	3.0%	·
Network opex/min	0.44	0.41	0.45	0.42	0.44	Has shown a sustained decline
EBITDA/min	0.52	0.68	0.67	0.69	0.77	
Coverage						
Network sites	11,338	11,912	12,703	13,628	14,112	Maintains capex guidance of US\$1.3-1.4bn

Source: Company, Citi Investment Research and Analysis

Bharti Airtel

Company description

Bharti Airtel, through its group companies, provides cellular-phone services in all of India's 23 telecom circles. The group also provides fixed-line phone services, broadband, long-distance and enterprise services. It is listed on The Stock Exchange, Mumbai (BSE) and The National Stock Exchange of India Limited (NSE). Major shareholders are Bharti Telecom, SingTel and Vodafone.

Investment strategy

We rate Bharti Buy with a target price of Rs425. The domestic business has witnessed slowed mins growth since the tariff hikes undertaken in July. With continued price arbitrage, we believe that Bharti will re-think its strategy of keeping tariffs high - the approach however is likely to be nuanced with selective cuts to regain lost mkt share. This while going against its strategy of keeping tariffs firm, may be necessitated by market dynamics. Longer-term we remain confident of the structural improvement in the telecom industry post license cancellation with 1) traffic migration and 2) higher visibility of spectrum. Competitive intensity should also somewhat abate. Further steady revenue stream of towerco (15% of EPS in the next 2 years) should also provide some stability to the earnings.

Initial signs emanating from Africa have been positive -1) sub adds have been healthy and 2) revenue growth has revived. While 3QFY12 saw some business disruption, we believe that healthy mins growth and cost efficiencies should manifest into healthier margins over the next 6-9 months.

Valuation

Our target price of Rs425 comprises: (i) Core business value of Rs320 based on Dec-12E DCF; (ii) we estimate value accretion from Africa acquisition at Rs39/share; (iii) We add the towerco value (100% Infratel + 42% of Indus) at Rs90; and (iv) We reduce the potential cash outgo (Rs24) related to one-time excess spectrum charges and license renewal fees. The DCF is based on a WACC of 11.2%, a terminal growth rate of 3% and beta of 0.8. We prefer DCF as peak capex burden is behind us and the company should start to generate significant free cash flows. The domestic business DCF implies FY13E EV/EBITDA of 7.1x, P/CEPS of 8.5x and P/E of 18.6x.

Risks

They key risks to our investment thesis and target price on Bharti are: 1) business disruption through slower-than-expected volume growth despite fine-tuning of tariffs in case the competition gets aggressive; 2) slower turnaround at acquisition; and 3) high regulatory cash outflows (low probability in our view). We however believe that the following factors help to mitigate downside risks: 1) Bharti has a track record of profitability and execution; and 2) strong FCF generation notwithstanding the high debt following an acquisition.

IDEA Cellular

(IDEA.BO; Rs92.25; 1)

Valuation

Our target price of Rs111 is based on (i) core business value at Rs113/share based on Mar-12 DCF; plus (ii) the Indus Towers stake valued at Rs15/share; minus (iii) Rs17 cash outgo related to one-time spectrum charges and license renewals from TRAI recommendations. The DCF is based on a WACC of 11.0%, a terminal growth rate of 3% and beta of 1.1. We prefer DCF as peak capex burden is behind us and the company should now start to generate free cash flows. The DCF implies a Mar13E EV/EBITDA value of 8.2x.

Risks

High leverage is a concern for Idea; it is however mitigated by the track record of superior execution that the management has established. The management has done an exceptional job in navigating through rough patch in the telecom sector in the past couple of years which is evident in the revenue share gains the company has made. As a result, we believe any risks arising from having a stretched B/S have reduced. Downside risks that could impede the stock from reaching our target price include: 1) Adverse regulations regulated to higher-than-expected regulatory charges (license fee renewals and excess spectrum charges) and a sharper than expected decline in traffic growth or revenue market share loss in case the competition doesn't match the tariff increases, which may also lead to a roll back.

Appendix A-1

Analyst Certification

The research analyst(s) primarily responsible for the preparation and content of this research report are named in bold text in the author block at the front of the product except for those sections where an analyst's name appears in bold alongside content which is attributable to that analyst. Each of these analyst(s) certify, with respect to the section(s) of the report for which they are responsible, that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc and its affiliates. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this report.

IMPORTANT DISCLOSURES





Citigroup Global Markets Inc. or its affiliates beneficially owns 1% or more of any class of common equity securities of IDEA Cellular. This position reflects information available as of the prior business day.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Bharti Airtel, IDEA Cellular in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, securities-related: Bharti Airtel, IDEA Cellular.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, non-securities-related: Bharti Airtel, IDEA Cellular.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Investment Research & Analysis product ("the Product"), please contact Citi Investment Research & Analysis, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citi Investment Research & Analysis Ratings Distribution

	1 Z IVIO	nın Katıı	1g	Relative Rating			
Data current as of 31 Dec 2011	Buy	Hold	Sell	Buy	Hold	Sell	
Citi Investment Research & Analysis Global Fundamental Coverage	57%	34%	9%	10%	79%	10%	
% of companies in each rating category that are investment banking clients	45%	41%	40%	49%	43%	41%	

40 M - -- 41- D - 41-- --

Guide to Citi Investment Research & Analysis (CIRA) Fundamental Research Investment Ratings:

CIRA's stock recommendations include an investment rating and an optional risk rating to highlight high risk stocks.

Risk rating takes into account both price volatility and fundamental criteria. Stocks will either have no risk rating or a High risk rating assigned. Investment Ratings: CIRA's investment ratings are Buy, Neutral and Sell. Our ratings are a function of analyst expectations of expected total return ("ETR") and risk. ETR is the sum of the forecast price appreciation (or depreciation) plus the dividend yield for a stock within the next 12 months. The Investment rating definitions are: Buy (1) ETR of 15% or more or 25% or more for High risk stocks; and Sell (3) for negative ETR. Any covered stock not assigned a Buy or a Sell is a Neutral (2). For stocks rated Neutral (2), if an analyst believes that there are insufficient valuation drivers and/or investment catalysts to derive a positive or negative investment view, they may elect with the approval of CIRA management not to assign a target price and, thus, not derive an ETR. Analysts may place covered stocks "Under Review" in response to exceptional circumstances (e.g. lack of information critical to the analyst's thesis) affecting the company and / or trading in the company's securities (e.g. trading suspension). As soon as practically possible, the analyst will publish a note re-establishing a rating and investment thesis. To satisfy regulatory requirements, we correspond Under Review and Neutral to Hold in our ratings distribution table for our 12-month fundamental rating system. However, we reiterate that we do not consider Under Review to be a recommendation. Relative three-month ratings: CIRA may also assign a three-month relative call (or rating) to a stock to highlight expected out-performance (most preferred) or under-performance (least preferred) versus the geographic and industry sector over a 3 month period. The relative call may highlight a specific near-term catalyst or event impacting the company or the market that is anticipated to have a short-term price impact on the equity securities of the company. Absent any specific catalyst the analyst(s) will indicate the most and least preferred stocks in the universe of stocks under consideration, explaining the basis for this short-term view. This three-month view may be different from and does not affect a stock's fundamental equity rating, which reflects a longer-term total absolute return expectation. For purposes of NASD/NYSE ratings-distribution-disclosure rules, most preferred calls correspond to a buy recommendation and least preferred calls correspond to a sell recommendation. Any stock not assigned to a most preferred or least preferred call is considered non-relative-rated (NRR). For purposes of NASD/NYSE ratings-distribution-disclosure rules we correspond NRR to Hold in our ratings distribution table for our 3-month relative rating system. However, we reiterate that we do not consider NRR to be a recommendation.

Prior to October 8, 2011, the firm's stock recommendation system included a risk rating and an investment rating. **Risk ratings**, which took into account both price volatility and fundamental criteria, were: Low (L), Medium (M), High (H), and Speculative (S). **Investment Ratings** of Buy, Hold and Sell were a function of CIRA's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating. Additionally, analysts could have placed covered stocks "Under Review" in response to exceptional circumstances (e.g. lack of information critical to the analyst's thesis) affecting the company and/or trading in the company's securities (e.g. trading suspension). Stocks placed "Under Review" were monitored daily by management and as practically possible, the analyst published a note re-establishing a rating and investment thesis. For securities in developed markets (US, UK, Europe, Japan, and Australia/New Zealand), investment ratings were:Buy (1) (expected total return of 10% or more for Low-Risk stocks, 15% or more for Medium-Risk stocks, 20% or more for High-Risk stocks, and 35% or more for Speculative stocks); Hold (2) (0%-10% for Low-Risk stocks, 0%-15% for Medium-Risk stocks, 0%-20% for High-Risk stocks, and 0%-35% for Speculative stocks); and Sell (3) (negative total return). For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings were:Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

Citigroup Global Markets India Private Limited	Gaurav Malhotra, CFA; Jitender Tokas
Citigroup Global Markets Asia	Ravi Sarathy

OTHER DISCLOSURES

The subject company's share price set out on the front page of this Product is quoted as at 08 February 2012 04:00 PM on the issuer's primary market.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Investment Research & Analysis (CIRA) does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of CIRA to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is n

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers: Morgan Stanley & Co. LLC (Morgan Stanley) research reports may be available about the companies that are the subject of this Citi Investment Research & Analysis (CIRA) research report. Ask your Financial Advisor or use smithbarney.com to view any available Morgan Stanley research reports in addition to CIRA research reports.

Important disclosure regarding the relationship between the companies that are the subject of this CIRA research report and Morgan Stanley Smith Barney LLC and its affiliates are available at the Morgan Stanley Smith Barney disclosure website at www.morganstanleysmithbarney.com/researchdisclosures. For Morgan Stanley and Citigroup Global Markets, Inc. specific disclosures, you may refer to www.morganstanley.com/researchdisclosures and https://www.citigroupgeo.com/geopublic/Disclosures/index_a.html.

This CIRA research report has been reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval was conducted by the same person who reviewed this research report on behalf of CIRA. This could create a conflict of interest.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in Brazil by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC -Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. This product is available in Chile through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros. Agustinas 975, piso 2, Santiago, Chile. The Product is made available in France by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 1-5 Rue Paul Cézanne, 8ème, Paris, France. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG ("CGMD"), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. Research which relates to "securities" (as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) is issued in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Limited which takes full responsibility for its content. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Research is made available through Citibank, N.A., Hong Kong Branch, for its clients in Citi Private Bank, it is made available by Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citibank N.A. is regulated by the Hong Kong Monetary Authority. Please contact your Private Banker in Citibank N.A., Hong Kong, Branch if you have any queries on or any matters arising from or in connection with this document. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in Indonesia through PT Citigroup Securities Indonesia. 5/F. Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kay. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with

applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in Israel through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A, Platinum Building, 21 Ha'arba'ah St, Tel Aviv, Israel. The Product is made available in Italy by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. Via dei Mercanti, 12, Milan, 20121, Italy. The Product is made available in Japan by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange, Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Global Equities Online (GEO) website. If you have questions regarding GEO, please call (81 3) 6270-3019 for help. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-gu, Seoul 110-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03030&pageDiv=02. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd (Company No. 460819-D) ("CGMM") to its clients and CGMM takes responsibility for its contents. CGMM is regulated by the Securities Commission of Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from, or in connection with, the Product. The Product is made available in **Mexico** by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comision Nacional Bancaria v de Valores, Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available to 'wholesale clients' only as defined by s5C(1) of the Financial Advisers Act 2008 ('FAA') through Citigroup Global Markets Australia Pty Ltd (ABN 64 003 114 832 and AFSL No. 240992), an overseas financial adviser as defined by the FAA, participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Pakistan by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the Philippines through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in the Philippines through Citibank NA Philippines branch, Citibank Tower, 8741 Paseo De Roxas, Makati City, Manila. Citibank NA Philippines NA is regulated by The Bangko Sentral ng Pilipinas. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd. ("CGMSPL"), a capital markets services license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192, in respect of any matters arising from, or in connection with, the analysis of this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore Branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). This report is distributed in Singapore by Citibank Singapore Ltd ("CSL") to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigold//Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this report. This report is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289). Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Spain by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 29 Jose Ortega Y Gassef, 4th Floor, Madrid, 28006, Spain. The Product is made available in the Republic of China through Citigroup Global Markets Taiwan Securities Company Ltd. ("CGMTS"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan and/or through Citibank Securities (Taiwan) Company Limited ("CSTL"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the respective license scope of each entity and the applicable laws and regulations in the Republic of China. CGMTS and CSTL are both regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China. No portion of the Product may be reproduced or quoted in the Republic of China by the press or any third parties [without the written authorization of CGMTS and CSTL]. If the Product covers securities which are not allowed to be offered or traded in the Republic of China, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products mentioned in the Product must take into account existing public information on such security or the financial products or any registered prospectus. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in Turkey through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the U.A.E, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different CIRA ratings distribution, in percentage terms for Investments in each sector

Bharti Airtel (BRTI.BO)

9 February 2012

covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in **United Kingdom** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in **United States** by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Pursuant to Comissão de Valores Mobiliários Rule 483, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to CIRA's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations.

The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product. With the exception of our product that is made available only to Qualified Institutional Buyers (QIBs), CIRA concurrently disseminates its research via proprietary and non-proprietary electronic distribution platforms. Periodically, individual CIRA analysts may also opt to circulate research posted on such platforms to one or more clients by email. Such email distribution is discretionary and is done only after the research has been disseminated via the aforementioned distribution channels. CIRA simultaneously distributes product that is limited to QIBs only through email distribution.

The level and types of services provided by CIRA analysts to clients may vary depending on various factors such as the client's individual preferences as to the frequency and manner of receiving communications from analysts, the client's risk profile and investment focus and perspective (e.g. market-wide, sector specific, long term, short-term etc.), the size and scope of the overall client relationship with Citi and legal and regulatory constraints.

© 2012 Citigroup Global Markets Inc. Citi Investment Research & Analysis is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, redisseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST